Literature DB >> 25981961

Expanding the spectrum of neuronal pathology in multiple system atrophy.

Matthew D Cykowski1, Elizabeth A Coon2, Suzanne Z Powell1, Sarah M Jenkins3, Eduardo E Benarroch2, Phillip A Low2, Ann M Schmeichel2, Joseph E Parisi4.   

Abstract

Multiple system atrophy is a sporadic alpha-synucleinopathy that typically affects patients in their sixth decade of life and beyond. The defining clinical features of the disease include progressive autonomic failure, parkinsonism, and cerebellar ataxia leading to significant disability. Pathologically, multiple system atrophy is characterized by glial cytoplasmic inclusions containing filamentous alpha-synuclein. Neuronal inclusions also have been reported but remain less well defined. This study aimed to further define the spectrum of neuronal pathology in 35 patients with multiple system atrophy (20 male, 15 female; mean age at death 64.7 years; median disease duration 6.5 years, range 2.2 to 15.6 years). The morphologic type, topography, and frequencies of neuronal inclusions, including globular cytoplasmic (Lewy body-like) neuronal inclusions, were determined across a wide spectrum of brain regions. A correlation matrix of pathologic severity also was calculated between distinct anatomic regions of involvement (striatum, substantia nigra, olivary and pontine nuclei, hippocampus, forebrain and thalamus, anterior cingulate and neocortex, and white matter of cerebrum, cerebellum, and corpus callosum). The major finding was the identification of widespread neuronal inclusions in the majority of patients, not only in typical disease-associated regions (striatum, substantia nigra), but also within anterior cingulate cortex, amygdala, entorhinal cortex, basal forebrain and hypothalamus. Neuronal inclusion pathology appeared to follow a hierarchy of region-specific susceptibility, independent of the clinical phenotype, and the severity of pathology was duration-dependent. Neuronal inclusions also were identified in regions not previously implicated in the disease, such as within cerebellar roof nuclei. Lewy body-like inclusions in multiple system atrophy followed the stepwise anatomic progression of Lewy body-spectrum disease inclusion pathology in 25.7% of patients with multiple system atrophy, including a patient with visual hallucinations. Further, the presence of Lewy body-like inclusions in neocortex, but not hippocampal alpha-synuclein pathology, was associated with cognitive impairment (P = 0.002). However, several cases had the presence of isolated Lewy body-like inclusions at atypical sites (e.g. thalamus, deep cerebellar nuclei) that are not typical for Lewy body-spectrum disease. Finally, interregional correlations (rho ≥ 0.6) in pathologic glial and neuronal lesion burden suggest shared mechanisms of disease progression between both discrete anatomic regions (e.g. basal forebrain and hippocampus) and cell types (neuronal and glial inclusions in frontal cortex and white matter, respectively). These findings suggest that in addition to glial inclusions, neuronal pathology plays an important role in the developmental and progression of multiple system atrophy.
© The Author (2015). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Lewy body-like; alpha-synuclein; inclusion bodies; multiple system atrophy; neuropathology

Mesh:

Substances:

Year:  2015        PMID: 25981961      PMCID: PMC4840945          DOI: 10.1093/brain/awv114

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  47 in total

Review 1.  Multiple system atrophy: a clinical and neuropathological perspective.

Authors:  Kiren Ubhi; Phillip Low; Eliezer Masliah
Journal:  Trends Neurosci       Date:  2011-09-29       Impact factor: 13.837

2.  Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy.

Authors:  J Q Trojanowski; T Revesz
Journal:  Neuropathol Appl Neurobiol       Date:  2007-12       Impact factor: 8.090

3.  Consensus paper: the cerebellum's role in movement and cognition.

Authors:  Leonard F Koziol; Deborah Budding; Nancy Andreasen; Stefano D'Arrigo; Sara Bulgheroni; Hiroshi Imamizu; Masao Ito; Mario Manto; Cherie Marvel; Krystal Parker; Giovanni Pezzulo; Narender Ramnani; Daria Riva; Jeremy Schmahmann; Larry Vandervert; Tadashi Yamazaki
Journal:  Cerebellum       Date:  2014-02       Impact factor: 3.847

4.  Participation of caudal fastigial nucleus in smooth pursuit eye movements. II. Effects of muscimol inactivation.

Authors:  F R Robinson; A Straube; A F Fuchs
Journal:  J Neurophysiol       Date:  1997-08       Impact factor: 2.714

5.  Grading of neuropathology in multiple system atrophy: proposal for a novel scale.

Authors:  Kurt A Jellinger; Klaus Seppi; Gregor K Wenning
Journal:  Mov Disord       Date:  2005-08       Impact factor: 10.338

6.  Lewy bodies in progressive supranuclear palsy represent an independent disease process.

Authors:  Hirotake Uchikado; Anthony DelleDonne; Zeshan Ahmed; Dennis W Dickson
Journal:  J Neuropathol Exp Neurol       Date:  2006-04       Impact factor: 3.685

7.  Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome).

Authors:  M I Papp; J E Kahn; P L Lantos
Journal:  J Neurol Sci       Date:  1989-12       Impact factor: 3.181

8.  Second consensus statement on the diagnosis of multiple system atrophy.

Authors:  S Gilman; G K Wenning; P A Low; D J Brooks; C J Mathias; J Q Trojanowski; N W Wood; C Colosimo; A Dürr; C J Fowler; H Kaufmann; T Klockgether; A Lees; W Poewe; N Quinn; T Revesz; D Robertson; P Sandroni; K Seppi; M Vidailhet
Journal:  Neurology       Date:  2008-08-26       Impact factor: 9.910

9.  Increased expression of ABCA8 in multiple system atrophy brain is associated with changes in pathogenic proteins.

Authors:  Jonathan M Bleasel; Jen-Hsiang T Hsiao; Glenda M Halliday; Woojin Scott Kim
Journal:  J Parkinsons Dis       Date:  2013-01-01       Impact factor: 5.568

Review 10.  The neuropathology, pathophysiology and genetics of multiple system atrophy.

Authors:  Z Ahmed; Y T Asi; A Sailer; A J Lees; H Houlden; T Revesz; J L Holton
Journal:  Neuropathol Appl Neurobiol       Date:  2012-02       Impact factor: 8.090

View more
  85 in total

1.  Glial α-synuclein promotes neurodegeneration characterized by a distinct transcriptional program in vivo.

Authors:  Abby L Olsen; Mel B Feany
Journal:  Glia       Date:  2019-07-03       Impact factor: 7.452

2.  Orthostatic heart rate changes in patients with autonomic failure caused by neurodegenerative synucleinopathies.

Authors:  Lucy Norcliffe-Kaufmann; Horacio Kaufmann; Jose-Alberto Palma; Cyndya A Shibao; Italo Biaggioni; Amanda C Peltier; Wolfgang Singer; Phillip A Low; David S Goldstein; Christopher H Gibbons; Roy Freeman; David Robertson
Journal:  Ann Neurol       Date:  2018-03-10       Impact factor: 10.422

3.  Neurite orientation dispersion and density imaging (NODDI) and free-water imaging in Parkinsonism.

Authors:  Trina Mitchell; Derek B Archer; Winston T Chu; Stephen A Coombes; Song Lai; Bradley J Wilkes; Nikolaus R McFarland; Michael S Okun; Mieniecia L Black; Ellen Herschel; Tanya Simuni; Cynthia Comella; Tao Xie; Hong Li; Todd B Parrish; Ajay S Kurani; Daniel M Corcos; David E Vaillancourt
Journal:  Hum Brain Mapp       Date:  2019-08-12       Impact factor: 5.038

Review 4.  Neuropathology of Parkinson disease.

Authors:  Dennis W Dickson
Journal:  Parkinsonism Relat Disord       Date:  2017-08-01       Impact factor: 4.891

5.  Multimodal MRI evaluation of parkinsonian limbic pathologies.

Authors:  Ernest W Wang; Guangwei Du; Mechelle M Lewis; Eun-Young Lee; Sol De Jesus; Sangam Kanekar; Lan Kong; Xuemei Huang
Journal:  Neurobiol Aging       Date:  2019-01-16       Impact factor: 4.673

6.  Epigallocatechin gallate in multiple system atrophy (PROMESA).

Authors:  Kurt A Jellinger
Journal:  Ann Transl Med       Date:  2019-12

Review 7.  Urological dysfunction in synucleinopathies: epidemiology, pathophysiology and management.

Authors:  Ryuji Sakakibara; Fuyuki Tateno; Tatsuya Yamamoto; Tomoyuki Uchiyama; Tomonori Yamanishi
Journal:  Clin Auton Res       Date:  2017-11-09       Impact factor: 4.435

8.  Profile of cognitive impairment and underlying pathology in multiple system atrophy.

Authors:  Shunsuke Koga; Adam Parks; Ryan J Uitti; Jay A van Gerpen; William P Cheshire; Zbigniew K Wszolek; Dennis W Dickson
Journal:  Mov Disord       Date:  2016-11-15       Impact factor: 10.338

Review 9.  The neuropathology of multiple system atrophy and its therapeutic implications.

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Auton Neurosci       Date:  2017-11-10       Impact factor: 3.145

Review 10.  Mesenchymal Stromal Cell Therapies for Neurodegenerative Diseases.

Authors:  Nathan P Staff; David T Jones; Wolfgang Singer
Journal:  Mayo Clin Proc       Date:  2019-05       Impact factor: 7.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.